CN110996988A - 稳定性优异的含有特立帕肽的液态药物组合物 - Google Patents

稳定性优异的含有特立帕肽的液态药物组合物 Download PDF

Info

Publication number
CN110996988A
CN110996988A CN201880053788.9A CN201880053788A CN110996988A CN 110996988 A CN110996988 A CN 110996988A CN 201880053788 A CN201880053788 A CN 201880053788A CN 110996988 A CN110996988 A CN 110996988A
Authority
CN
China
Prior art keywords
component
salt
liquid pharmaceutical
teriparatide
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880053788.9A
Other languages
English (en)
Chinese (zh)
Inventor
宫部康平
山口贵宏
松绳保宏
渡边成实
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Priority to CN202311111773.2A priority Critical patent/CN116898955A/zh
Publication of CN110996988A publication Critical patent/CN110996988A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201880053788.9A 2017-09-22 2018-09-20 稳定性优异的含有特立帕肽的液态药物组合物 Pending CN110996988A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311111773.2A CN116898955A (zh) 2017-09-22 2018-09-20 稳定性优异的含有特立帕肽的液态药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-182611 2017-09-22
JP2017182611 2017-09-22
PCT/JP2018/034887 WO2019059302A1 (ja) 2017-09-22 2018-09-20 安定性に優れるテリパラチド含有液状医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311111773.2A Division CN116898955A (zh) 2017-09-22 2018-09-20 稳定性优异的含有特立帕肽的液态药物组合物

Publications (1)

Publication Number Publication Date
CN110996988A true CN110996988A (zh) 2020-04-10

Family

ID=65811407

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880053788.9A Pending CN110996988A (zh) 2017-09-22 2018-09-20 稳定性优异的含有特立帕肽的液态药物组合物
CN202311111773.2A Pending CN116898955A (zh) 2017-09-22 2018-09-20 稳定性优异的含有特立帕肽的液态药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311111773.2A Pending CN116898955A (zh) 2017-09-22 2018-09-20 稳定性优异的含有特立帕肽的液态药物组合物

Country Status (6)

Country Link
US (2) US20200289621A1 (enExample)
EP (1) EP3685849A4 (enExample)
JP (17) JP6577683B2 (enExample)
CN (2) CN110996988A (enExample)
CA (1) CA3075977C (enExample)
WO (1) WO2019059302A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111447943A (zh) * 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
CN114316021A (zh) * 2021-12-29 2022-04-12 江苏诺泰澳赛诺生物制药股份有限公司 一种特立帕肽及的纯化方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
JP7240407B2 (ja) * 2019-09-05 2023-03-15 旭化成ファーマ株式会社 テリパラチド又はその塩を含有する無菌注射剤を製造する方法
WO2021117735A1 (ja) * 2019-12-09 2021-06-17 旭化成ファーマ株式会社 テリパラチド又はその塩を含有するプレフィルドシリンジまたはカートリッジ製剤の振盪による白濁を抑制する方法
CN114845701A (zh) * 2019-12-18 2022-08-02 株式会社大熊制药 1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺的液体药物组合物
WO2021229835A1 (ja) * 2020-05-11 2021-11-18 旭化成ファーマ株式会社 テリパラチド又はその塩を含有する安定な液状医薬製剤
CN114306249A (zh) * 2020-09-28 2022-04-12 深圳翰宇药业股份有限公司 一种特立帕肽冻干药物组合物及其制备方法
CN114031680B (zh) * 2021-09-01 2024-03-26 浙江湃肽生物有限公司 一种索玛鲁肽钠盐及其制备方法与应用
WO2025032376A1 (en) * 2023-08-04 2025-02-13 Precise Biopharma Pvt Ltd A room temperature stable solution for injection of abaloparatide

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1281370A (zh) * 1997-12-09 2001-01-24 伊莱利利公司 稳定的特立帕肽溶液
CN1319003A (zh) * 1998-04-28 2001-10-24 Nps阿尔利克斯公司 蛋白质制剂
JP2004010511A (ja) * 2002-06-05 2004-01-15 Asahi Kasei Corp Ｐｔｈの安定化水溶液注射剤
US20060211054A1 (en) * 2001-04-03 2006-09-21 Armbruster Franz P Method for determining effective parathormone activity in a sample
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
CN1997319A (zh) * 2004-05-13 2007-07-11 阿尔扎公司 甲状旁腺激素药物的透皮释放装置和方法
JP2007186466A (ja) * 2006-01-16 2007-07-26 Asahi Kasei Pharma Kk 樹脂容器中の生理活性ペプチドの安定性改善方法
WO2008016404A2 (en) * 2006-07-31 2008-02-07 Zelos Therapeutics, Inc. Parathyroid hormone analogues and uses thereof
WO2009053106A1 (en) * 2007-10-26 2009-04-30 Nycomed Danmark Aps Parathyroid hormone formulations and uses thereof
WO2011011675A1 (en) * 2009-07-23 2011-01-27 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
CN102470164A (zh) * 2009-09-09 2012-05-23 旭化成制药株式会社 以每周给药1次每次为100单位～200单位的pth为特征的、含有pth的骨质疏松症治疗/预防剂
WO2012075375A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
US20150011473A1 (en) * 2012-01-20 2015-01-08 Lupin Limited Stabilized pth formulation
WO2017007777A2 (en) * 2015-07-06 2017-01-12 Zhengxin Dong NOVEL FORMULATIONS OF PTHrP ANALOGUE

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6357527A (ja) 1986-08-28 1988-03-12 Toyo Jozo Co Ltd 薬剤の吸着防止方法
JPH0669956B2 (ja) 1988-09-30 1994-09-07 旭化成工業株式会社 ポリペプタイド類の吸着防止剤
NL9001681A (nl) * 1990-07-24 1992-02-17 Rijksuniversiteit Transmucosale geneesmiddelpreparaten en transmucosale toediening.
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
JPH11235390A (ja) * 1997-12-12 1999-08-31 Takeda Chem Ind Ltd 経皮透過方法
PL341209A1 (en) * 1997-12-18 2001-03-26 Lilly Co Eli Crystalline teriparatide
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
JP2004513069A (ja) 2000-05-19 2004-04-30 レストラゲン，インコーポレイテッド ペプチド医薬処方
US20040097883A1 (en) * 2000-10-09 2004-05-20 Roe Michael Joseph Pen device for administration of parathyroid hormone
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
US6896894B2 (en) * 2001-10-30 2005-05-24 Battelle Memorial Institute Proteins stabilized with polysaccharide gums
AU2002363412A1 (en) * 2001-11-05 2003-05-19 Eli Lilly And Company Method for improving stability of a bone-connecting implant
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
WO2005014034A1 (en) * 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
JP4707327B2 (ja) 2004-01-27 2011-06-22 旭化成ファーマ株式会社 ポリペプタイド類の吸着防止剤
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
EP1744683B1 (en) * 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
JP4951344B2 (ja) * 2004-08-24 2012-06-13 第一三共株式会社 生理活性ペプチド液状製剤
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
CA2625084A1 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
DK3091075T3 (en) * 2007-04-09 2018-07-16 Univ Arkansas FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYRO OIDA HORMON
JP5362715B2 (ja) * 2007-06-29 2013-12-11 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 高温で使用するためのｇｄｆ−５を含む液体タンパク質製剤
US7947649B2 (en) * 2008-04-14 2011-05-24 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
KR20110076918A (ko) * 2008-09-10 2011-07-06 제넨테크, 인크. 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
KR101676887B1 (ko) * 2008-11-20 2016-11-16 제넨테크, 인크. 치료 단백질 제형
JP2009091363A (ja) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
US8481678B2 (en) 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
WO2011139838A2 (en) 2010-04-28 2011-11-10 Zelos Therapeutics, Inc. Intranasal formulations
BR112013023062B1 (pt) 2011-03-10 2022-01-18 Xeris Pharmaceuticals, Inc Solução estável para a injeção parenteral e método de fabricação da mesma
KR101891673B1 (ko) 2011-06-07 2018-08-27 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
WO2013063277A1 (en) * 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
NZ631445A (en) * 2012-04-09 2017-02-24 Daiichi Sankyo Co Ltd Anti-fgfr2 antibody
EP3209332B1 (en) * 2014-10-23 2021-05-26 Amgen Inc. Reducing viscosity of pharmaceutical formulations
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
JP6641870B2 (ja) * 2015-10-14 2020-02-05 ニプロ株式会社 パラサイロイドホルモン類含有製剤の製造方法
JP2018188399A (ja) * 2017-05-10 2018-11-29 ニプロ株式会社 テリパラチドのプレフィルドシリンジ製剤
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1281370A (zh) * 1997-12-09 2001-01-24 伊莱利利公司 稳定的特立帕肽溶液
CN1319003A (zh) * 1998-04-28 2001-10-24 Nps阿尔利克斯公司 蛋白质制剂
US20060211054A1 (en) * 2001-04-03 2006-09-21 Armbruster Franz P Method for determining effective parathormone activity in a sample
JP2004010511A (ja) * 2002-06-05 2004-01-15 Asahi Kasei Corp Ｐｔｈの安定化水溶液注射剤
CN1997319A (zh) * 2004-05-13 2007-07-11 阿尔扎公司 甲状旁腺激素药物的透皮释放装置和方法
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
JP2007186466A (ja) * 2006-01-16 2007-07-26 Asahi Kasei Pharma Kk 樹脂容器中の生理活性ペプチドの安定性改善方法
WO2008016404A2 (en) * 2006-07-31 2008-02-07 Zelos Therapeutics, Inc. Parathyroid hormone analogues and uses thereof
WO2009053106A1 (en) * 2007-10-26 2009-04-30 Nycomed Danmark Aps Parathyroid hormone formulations and uses thereof
WO2011011675A1 (en) * 2009-07-23 2011-01-27 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
CN102470164A (zh) * 2009-09-09 2012-05-23 旭化成制药株式会社 以每周给药1次每次为100单位～200单位的pth为特征的、含有pth的骨质疏松症治疗/预防剂
WO2012075375A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
US20150011473A1 (en) * 2012-01-20 2015-01-08 Lupin Limited Stabilized pth formulation
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
WO2017007777A2 (en) * 2015-07-06 2017-01-12 Zhengxin Dong NOVEL FORMULATIONS OF PTHrP ANALOGUE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
无: "\"FORTEO - HIGHLIGHTS OF PRESCRIBING INFORMATION\"", pages 1 - 15 *
陈慧鹏: "《医学生物工程进展》", 人民军医出版社, pages: 165 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111447943A (zh) * 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
CN114316021A (zh) * 2021-12-29 2022-04-12 江苏诺泰澳赛诺生物制药股份有限公司 一种特立帕肽及的纯化方法

Also Published As

Publication number Publication date
JP2021046452A (ja) 2021-03-25
JP6581741B2 (ja) 2019-09-25
JP2020114843A (ja) 2020-07-30
US20200289621A1 (en) 2020-09-17
JP6817358B2 (ja) 2021-01-20
JP6851536B2 (ja) 2021-03-31
CA3075977C (en) 2024-10-29
JP6977137B2 (ja) 2021-12-08
JP6825034B2 (ja) 2021-02-03
JP6781790B2 (ja) 2020-11-04
JP2021088606A (ja) 2021-06-10
EP3685849A4 (en) 2021-12-22
JP6577683B2 (ja) 2019-09-18
JP2019116513A (ja) 2019-07-18
JP6766286B2 (ja) 2020-10-07
JP2020040995A (ja) 2020-03-19
US20210205418A1 (en) 2021-07-08
JP6585317B2 (ja) 2019-10-02
CN116898955A (zh) 2023-10-20
JP2019065042A (ja) 2019-04-25
EP3685849A1 (en) 2020-07-29
JP6646173B2 (ja) 2020-02-14
JP2019089862A (ja) 2019-06-13
JP6739612B2 (ja) 2020-08-12
JP2021036000A (ja) 2021-03-04
JP6634175B2 (ja) 2020-01-22
WO2019059302A1 (ja) 2019-03-28
JP2019073543A (ja) 2019-05-16
JP2019089863A (ja) 2019-06-13
JP2019081811A (ja) 2019-05-30
JP6818928B2 (ja) 2021-01-27
JP2019081812A (ja) 2019-05-30
CA3075977A1 (en) 2019-03-28
JPWO2019059302A1 (ja) 2019-11-14
JP2019089864A (ja) 2019-06-13
JP6714738B2 (ja) 2020-06-24
JP6826140B2 (ja) 2021-02-03
JP2020186270A (ja) 2020-11-19
JP2019089865A (ja) 2019-06-13
JP2019116495A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
JP6851536B2 (ja) 安定性に優れるテリパラチド含有液状医薬組成物
US20220096414A1 (en) Levothyroxine liquid formulations
HK40023299A (en) Teriparatide-containing liquid pharmaceutical composition having excellent stability
WO2019176239A1 (ja) 容器充填ヒトｐｔｈ（１－３４）液体医薬組成物及びその製造方法
US20110034399A1 (en) Liquid and Freeze Dried Formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40023299

Country of ref document: HK